+ +

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:1K dilution for 1 hour at room temperature.    

  
  

ICAM-1 (Intercellular Adhesion Molecule 1), also known as CD54. is a cell surface glycoprotein belonging to the immunoglobulin superfamily. It plays a critical role in mediating leukocyte adhesion and trafficking during inflammatory responses. Expressed on endothelial cells, immune cells, and other cell types, ICAM-1 interacts with integrins like LFA-1 (lymphocyte function-associated antigen 1) to facilitate immune cell recruitment to sites of infection, injury, or immune activation. Its expression is upregulated by pro-inflammatory cytokines (e.g., TNF-α, IL-1) or microbial stimuli, making it a key biomarker in inflammatory and autoimmune diseases, atherosclerosis, and cancer metastasis.

ICAM1/CD54 antibodies are tools used to detect or modulate ICAM-1 activity in research and therapeutic contexts. As detection reagents, they enable visualization of ICAM-1 expression in tissues (e.g., via immunohistochemistry) or quantification in soluble form (sICAM-1) in bodily fluids, aiding disease monitoring. Functionally, blocking antibodies inhibit ICAM-1/LFA-1 interactions, suppressing leukocyte adhesion in preclinical models of inflammation, transplant rejection, or autoimmune disorders. While therapeutic applications remain largely experimental, some antibody-based strategies have entered clinical trials for conditions like acute lung injury. These antibodies are also vital in studying ICAM-1's roles in viral entry (e.g., rhinoviruses) and tumor microenvironment modulation. Cross-reactivity with ICAM-1 orthologs in mice, rats, or primates supports translational research.